Adenosinergic cardioprotection: multiple receptors, multiple pathways - PubMed (original) (raw)
Review
Adenosinergic cardioprotection: multiple receptors, multiple pathways
Jason N Peart et al. Pharmacol Ther. 2007 May.
Abstract
Adenosine, formed primarily via hydrolysis of 5'-AMP, has been historically dubbed a "retaliatory" metabolite due to enhanced local release and beneficial actions during cellular/metabolic stress. From a cardiovascular perspective, evidence indicates the adenosinergic system is essential in mediation of intrinsic protection (e.g., pre- and postconditioning) and determining myocardial resistance to insult. Modulation of adenosine and its receptors thus remains a promising, though as yet not well-realized, approach to amelioration of injury in ischemic-reperfused myocardium. Adenosine exerts effects through A(1), A(2A), A(2B), and A(3) adenosine receptor subtypes (A(1)AR, A(2A)AR, A(2B)AR, and A(3)AR), which are all expressed in myocardial and vascular cells, and couple to G proteins to trigger a range of responses (generally, but not always, beneficial). Adenosine can also enhance tolerance to injurious stimuli via receptor-independent metabolic effects. Given adenosines contribution to preconditioning, it is no surprise that postreceptor signaling typically mimics that associated with preconditioning. This involves activation/translocation of PKC, PI3 kinase, and MAPKs, with ultimate effects at the level of mitochondrial targets-the mitochondrial K(ATP) channel and/or the mitochondrial permeability transition pore (mPTP). Nonetheless, differences in cytoprotective signaling and actions of the different adenosine receptor subtypes have been recently revealed. Our understanding of adenosinergic cytoprotection continues to evolve, with roles for the A(2) subtypes emerging, together with evidence of essential receptor "cross-talk" in mediation of protection. This review focuses on current research into adenosine-mediated cardioprotection, highlighting recent findings which, together with a wealth of prior knowledge, may ultimately facilitate adenosinergic approaches to clinical cardiac protection.
Similar articles
- Adenosine: trigger and mediator of cardioprotection.
Cohen MV, Downey JM. Cohen MV, et al. Basic Res Cardiol. 2008 May;103(3):203-15. doi: 10.1007/s00395-007-0687-7. Epub 2007 Nov 12. Basic Res Cardiol. 2008. PMID: 17999026 Review. - Adenosine-mediated cardioprotection in the aging myocardium.
Willems L, Ashton KJ, Headrick JP. Willems L, et al. Cardiovasc Res. 2005 May 1;66(2):245-55. doi: 10.1016/j.cardiores.2004.11.008. Epub 2004 Nov 23. Cardiovasc Res. 2005. PMID: 15820193 Review. - Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.
Ferdinandy P, Schulz R, Baxter GF. Ferdinandy P, et al. Pharmacol Rev. 2007 Dec;59(4):418-58. doi: 10.1124/pr.107.06002. Epub 2007 Nov 29. Pharmacol Rev. 2007. PMID: 18048761 Review. - Postconditioning--A new link in nature's armor against myocardial ischemia-reperfusion injury.
Vinten-Johansen J, Zhao ZQ, Zatta AJ, Kin H, Halkos ME, Kerendi F. Vinten-Johansen J, et al. Basic Res Cardiol. 2005 Jul;100(4):295-310. doi: 10.1007/s00395-005-0523-x. Epub 2005 Mar 30. Basic Res Cardiol. 2005. PMID: 15793629 Review. - Sustained cardioprotection: exploring unconventional modalities.
Peart JN, Headrick JP. Peart JN, et al. Vascul Pharmacol. 2008 Aug-Sep;49(2-3):63-70. doi: 10.1016/j.vph.2008.07.001. Epub 2008 Jul 13. Vascul Pharmacol. 2008. PMID: 18675381 Review.
Cited by
- Serum 5'-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease.
Aimaitijiang M, Wu TT, Zheng YY, Hou XG, Yang H, Yang Y, Xie X. Aimaitijiang M, et al. Rev Cardiovasc Med. 2024 Jan 10;25(1):17. doi: 10.31083/j.rcm2501017. eCollection 2024 Jan. Rev Cardiovasc Med. 2024. PMID: 39077643 Free PMC article. - Role of cAMP in Cardiomyocyte Viability: Beneficial or Detrimental?
Zhang Y, Chen S, Luo L, Greenly S, Shi H, Xu JJ, Yan C. Zhang Y, et al. Circ Res. 2023 Nov 10;133(11):902-923. doi: 10.1161/CIRCRESAHA.123.322652. Epub 2023 Oct 18. Circ Res. 2023. PMID: 37850368 - Effect of chronic maternal L-Glu intake during gestation and/or lactation on oxidative stress markers, AMPA Glu1 receptor and adenosine A1 signalling pathway from foetal and neonatal cerebellum.
Tejero A, León-Navarro DA, Martín M. Tejero A, et al. Purinergic Signal. 2024 Apr;20(2):181-192. doi: 10.1007/s11302-023-09959-6. Epub 2023 Jul 17. Purinergic Signal. 2024. PMID: 37458955 Free PMC article. - Endless Journey of Adenosine Signaling in Cardioprotective Mechanism of Conditioning Techniques: Clinical Evidence.
Kumar K, Singh N, Yadav HN, Maslov L, Jaggi AS. Kumar K, et al. Curr Cardiol Rev. 2023;19(6):56-71. doi: 10.2174/1573403X19666230612112259. Curr Cardiol Rev. 2023. PMID: 37309766 Free PMC article. Review. - Transcriptomic Profiling Unravels Novel Deregulated Gene Signatures Associated with Acute Myocardial Infarction: A Bioinformatics Approach.
Kumar S, Shih CM, Tsai LW, Dubey R, Gupta D, Chakraborty T, Sharma N, Singh AV, Swarup V, Singh HN. Kumar S, et al. Genes (Basel). 2022 Dec 9;13(12):2321. doi: 10.3390/genes13122321. Genes (Basel). 2022. PMID: 36553589 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials